| Autor: |
Pooja Hingorani, Mark Krailo, Allen Buxton, Paul Hutson, Paul M. Sondel, Mitchell Diccianni, Alice Yu, Carol D. Morris, Richard B. Womer, Brian Crompton, R Lor Randall, Lisa A. Teot, Steven G. DuBois, Katherine A. Janeway, Richard G. Gorlick, Michael S. Isakoff |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European Journal of Cancer. 172:264-275 |
| ISSN: |
0959-8049 |
| Popis: |
Novel effective therapies are urgently needed in recurrent osteosarcoma. GD2 is expressed in human osteosarcoma tumours and cell lines. This study evaluated the disease control rate (DCR) in patients with recurrent osteosarcoma treated with the anti-GD2 antibody dinutuximab plus cytokine therapy as compared to historical outcomes.AOST1421 was a single-arm Phase 2 study for patients with recurrent pulmonary osteosarcoma in complete surgical remission. Patients received up to five cycles of dinutuximab (70 mg/mThirty-nine eligible patients were included in the outcome analysis. Dinutuximab did not demonstrate evidence of efficacy as 11/39 patients remained event free for a DCR of 28.2% (95% CI 15-44.9%). One of 136 administered therapy cycles met criteria for unacceptable toxicity when a patient experienced sudden death of unknown cause. Other ≥ Grade 3 toxicities included pain, diarrhoea, hypoxia, and hypotension. Pharmacokinetic parameters were similar in the two schedules.The combination of dinutuximab with GM-CSF did not significantly improve DCR in recurrent osteosarcoma. Dinutuximab toxicity and pharmacokinetics in adolescent and young adult osteosarcoma patients were similar to younger patients. Other strategies for targeting GD2 in osteosarcoma are being developed. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect